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1. Introduction
The WHO Expert Committee on Drug Dependence met in Geneva from 
28 to 31 March 2006. Dr Howard Zucker, Assistant Director-General, 
Health Technology and Pharmaceuticals, and Dr Hans Hogerzeil, Director 
of Medicines Policy and Standards, welcomed the participants. Dr Zucker 
stressed the importance of balancing the need for preventing diversion of 
therapeutic substances with abuse potential by means of appropriate con-
trols against the need for ensuring access to these substances for therapeutic 
use. The data from the International Narcotics Control Board (INCB) show 
that in many countries there is underuse of the narcotic analgesics needed 
for patients. 
Dr Hogerzeil emphasized that the evaluation of substances by this Committee 
is one of the few tasks of WHO, if not the only one, based on international 
treaties. It is a mandatory task.
The meeting was opened by Dr L. Rägo, Coordinator, Quality Assurance 
and Safety: Medicines, who emphasized the signifi cant role this Committee 
has played in the implementation of the international drug control system 
based on the existing drug control Conventions. As a specialized agency of 
the United Nations, WHO is responsible for conducting the medical and sci-
entifi c evaluation of dependence-producing substances and makes recom-
mendations to the Commission on Narcotic Drugs of the United Nations 
concerning the level of international control to be applied to them. As WHO 
has the sole responsibility for this function, no psychoactive substance can 
be controlled internationally without fi rst being evaluated by WHO. 
2. Critical review of psychoactive substances
A critical review is conducted by the Expert Committee in any of the 
following cases: 
(1) There has been notifi cation from a Party to the 1961 (1) or the 1971 
Convention (2) concerning the scheduling of a substance. 
(2) There has been an explicit request from the United Nations Commis-
sion on Narcotic Drugs to review a substance. 
(3) Pre-review of a substance has resulted in a recommendation for critical 
review. 
(4) Information is brought to the attention of WHO that a substance pre-
senting an especially serious risk to public health and society, and of 
no recognized therapeutic use by any Member State is clandestinely 
manufactured. 
1
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2If therapeutic use of the substance is confi rmed subsequently by any Member 
State in respect of case (4), the substance shall be subject to a pre-review.
Three of the substances under critical review at the present meeting had 
been pre-reviewed at the thirty-third meeting of the Committee (3) and 
recommended for critical review. Two of the substances (buprenorphine and 
dronabinol) had undergone critical review at the previous meeting.
2.1 Substances recommended for changes in scheduling
2.1.1 Dronabinol (INN)
Substance identifi cation
Dronabinol (INN) is (6aR,10aR)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-
pentyl-6-H-dibenzo[b, d]pyran-1-ol. It is the (6aR,10aR)-stereoisomer of 
delta-9-tetrahydrocannabinol and is also designated (–)-trans-delta-9-tetra-
hydrocannabinol. 
Other stereoisomers of delta-9-tetrohydrocannabinol are: (6aR,10aS)-, 
(6aS,10aR)- and (6aS,10aS)-, also known as (–)-cis-, (+)-cis- and (+)-
trans-, respectively. Delta-9-tetrohydrocannabinol has two racemates, 
(6aRS,10aRS)- and (6aRS,10aSR)-, also known as (±)-trans- and (±)-cis-, 
respectively.
Originally, all isomers of tetrahydrocannabinol were included in Schedule I 
of the 1971 Convention. This was later amended to include seven named 
constitutional isomers and their respective stereochemical variants. The 
term “constitutional isomers” used above has recently been introduced by 
the International Union of Pure and Applied Chemistry (IUPAC) to replace 
the traditionally used term “positional isomers”. 
The term “stereochemical variants” used in the 1971 Convention and men-
tioned above is equivalent to the term “stereoisomers”, which is at present 
much more widely used in the chemical and related literature. Both terms 
cover geometric isomers and optical isomers.
Previous review
Delta-9-tetrahydrocannabinol was included in Schedule I of the 1971 Con-
vention at the time of its adoption. At its twenty-sixth meeting, the Com-
mittee recommended that dronabinol be moved to Schedule II, while keep-
ing the other isomers and their stereochemical variants in Schedule I (4). 
This proposal was rejected at the 11th Special Session of the Commission 
on Narcotic Drugs, and the Committee reviewed the question again at its 
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3twenty-seventh meeting when it recommended that all the stereochemical 
variants of delta-9-tetrahydrocannabinol be rescheduled to Schedule II (5). 
This recommendation was adopted by the United Nations Commission on 
Narcotic Drugs at its 34th session (6). At its thirty-second meeting, the 
Committee pre-reviewed dronabinol and recommended its critical review 
for consideration of the rescheduling on the grounds that the rate of abuse 
of dronabinol was extremely low (7). 
Delta-9-tetrahydrocannabinol was critically reviewed by the Expert Com-
mittee on Drug Dependence at its thirty-third meeting in September 2002 
(3). On the basis of the available data the Committee considered that 
dronabinol should be rescheduled to Schedule IV of the 1971 Convention. 
However, no further procedural steps were taken. Therefore, the existing 
critical review report was updated, including information from recent 
scientifi c publications, to enable the Committee to fi nalize the process 
of critical review. 
Similarity to known substances and effects on the central nervous system
Dronabinol is the main active principle of cannabis and has similar effects 
on mood, perception and the cardiovascular system. The cannabis plant 
contains a “natural mixture” of around 70 different cannabinoids, and also 
contains fl avonoids and terpenes, as well as many other substances. There-
fore the pharmacological properties of natural cannabis and dronabinol are 
not identical. 
Dependence potential
Animal studies have demonstrated that, like other drugs of abuse, dronabi-
nol acts as a drug reinforcer. Physical dependence, as shown by withdrawal 
syndrome following chronic administration, has also been demonstrated. 
Reinforcing effects and physical dependence have also been described in 
human studies.
Actual abuse and/or evidence of likelihood of abuse
The abuse of dronabinol is currently rare and there have been very few 
specifi c reports of its occurrence. In response to the WHO questionnaires 
only the United States mentioned instances of abuse of delta-9-tetrahydro-
cannabinol. At present, the quantity produced by licit manufacture is lim-
ited. In the United States, which is the major manufacturing country, the 
abuse of dronabinol medicinal preparations is reported to be very low and 
there are no reports of diversion of the pharmaceutical product.
TRS942.indd   3 3.1.2007   16:53:28
4Therapeutic usefulness
Dronabinol preparations have been used in a limited number of countries in 
the treatment of nausea and vomiting associated with cancer chemotherapy 
in patients who have failed to respond adequately to conventional anti-
emetic treatments and in the treatment of anorexia associated with weight 
loss in patients with acquired immunodefi ciency syndrome (AIDS). It has 
also been indicated in the treatment of chronic pain (e.g. in multiple 
sclerosis, neuropathic disorders and arthritis), neurological disorders and 
appetite loss in cachexia, and is being evaluated for use in various other 
clinical situations. 
Recommendation
The Committee reconsidered the recommendation of the thirty-third Expert 
Committee after considering the updated critical review report. The Com-
mittee concluded that dronabinol constitutes a substantial risk to public 
health. However this risk is different from those related to cannabis — con-
trolled under the 1961 Convention. The substance has a moderate therapeu-
tic usefulness and as a result of continuing clinical research its medical use 
is likely to increase. Therefore, the Committee recommended that dronabi-
nol (INN) and its stereoisomers should be rescheduled from Schedule II to 
Schedule III of the 1971 Convention.
To avoid legal and forensic chemical problems that may arise in some coun-
tries when placing stereoisomers of the same substance under different con-
trol systems, the Committee indicated that the recommendation pertains to all 
stereoisomeric forms of delta-9-tetrahydrocannabinol as specifi ed above.
2.1.2 Oripavine
Substance identifi cation
Oripavine, 3-O-demethylthebaine, or 6,7,8,14-tetradehydro-4,5-alpha-epoxy-
6-methoxy-17-methylmorphinan-3-ol is a phenanthrene alkaloid contained 
in species of the Papaver plant. It is a major metabolite of thebaine.
Previous review
Oripavine was pre-reviewed at the thirty-third meeting of the Expert Com-
mittee in 2002 (3). The reason for pre-review in 2002 was that oripavine is 
a substance that is convertible into thebaine, and because thebaine is in turn 
convertible into morphine. Thebaine and morphine are both in Schedule I 
of the 1961 Convention. Owing to uncertainties regarding the schedul-
ing of oripavine based on the additional possibility of applying the 1988 
TRS942.indd   4 3.1.2007   16:53:28
5Convention (8), the Committee did not fi nalize this review at its thirty-
third meeting, but asked WHO for clarifi cation of issues related to the 
conversion of precursors into scheduled substances. Subsequent clarifi ca-
tion of these issues allowed the Committee to come to a conclusion at its 
thirty-fourth meeting.
Recommendation
The Committee decided that oripavine is a substance that is easily convertible 
into thebaine and other substances controlled in Schedule I of the 1961 
Convention. Hence, the Committee recommended that oripavine be scheduled, 
like the substances mentioned, in Schedule I of the 1961 Convention.
2.2 Other substances critically reviewed
2.2.1 Buprenorphine (INN)
Substance identifi cation
Buprenorphine (INN) is chemically 21-cyclopropyl-7-alpha-[(S)-1-hydroxy-
1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine 
(CAS 53152-21-9 for the hydrochloride; 52485-79-7 for the free base). 
Previous review
In 1989, a decision of the United Nations Commission on Narcotic Drugs 
placed buprenorphine (INN) in Schedule III of the Convention on Psy-
chotropic Substances (1971 Convention). The decision followed the 
recommendation of the Expert Committee on Drug Dependence at its 
twenty-fi fth meeting (9). During its thirty-second meeting in 2000 (7), the 
Committee considered the question of the scheduling of buprenorphine 
and recommended critical review of the substance, taking into account a 
request by the INCB, as well as questions concerning the rationale for the 
control of this substance under the 1971 Convention rather than the 1961 
Single Convention.
At its thirty-third meeting, the Committee commenced the critical review 
of the scheduling of buprenorphine on the basis of a review document pro-
duced by the Secretariat (3). The Committee considered that buprenorphine 
met the requirements both for scheduling in the 1961 Convention and for its 
present scheduling in the 1971 Convention. However, taking any decision 
was hindered by a lack of authoritative guidance on the choice between the 
two possibilities. Therefore, the Expert Committee had to seek guidance for 
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appreciation of the impact of changes in the scheduling on public health.
New information since 2002
A document provided by the Secretariat for the thirty-fourth meeting of the 
Committee indicated an expansion in the therapeutic role of buprenorphine. 
Buprenorphine (and other medicines used in agonist pharmacotherapy of 
opioid dependence, such as methadone) is recognized as an effi cacious and 
cost-effective treatment for opioid dependence. Buprenorphine maintenance 
treatment programmes provide opportunities for human immunodefi ciency 
virus (HIV)/AIDS prevention among opioid-dependent injecting drug 
users and also support the implementation of directly observed antiretro-
viral therapy (ART) for people with opioid dependence who also have HIV/
AIDS. Buprenorphine maintenance treatment programmes can also act as 
a platform for promoting adherence to medical treatment of opportunistic 
infections. Buprenorphine maintenance treatment was stated to be available 
in about 30 countries. In March 2005, WHO included buprenorphine in 
the 14th WHO Model List of Essential Medicines for use in opioid agonist 
therapy of opioid dependence (10).
Data were presented to the Committee demonstrating unique pharmaco-
logical actions of buprenorphine, which distinguish it from other opioids 
controlled under the Single Convention. Specifi cally, buprenorphine is also 
an agonist at the ORL-1 receptor in the brain, which affects its µ-opioid 
actions. These new fi ndings suggest that buprenorphine has a unique spec-
trum of pharmacological actions.
There have been reports of diversion, seizures and abuse of buprenor-
phine in various countries. It was reported that in many instances 
buprenorphine was being illegally used for alleviating symptoms of opioid 
withdrawal.
Additional considerations
Additional documents presented to the Committee at its thirty-fourth meet-
ing dealt primarily with the possible effects of rescheduling buprenorphine 
from the 1971 Convention to the 1961 Convention.
The Committee was informed that this question had been discussed during 
the 115th meeting of the WHO Executive Board. It was indicated during the 
discussion that the transfer of substances from one convention to the other 
would result in problems with implementation of the conventions in national 
laws. A concern was expressed that transfer could consequently give rise to 
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7rescheduling at the national level, which would have the unintended effect 
of restricting access to buprenorphine for use in opioid agonist therapy. Of 
the 56 countries that responded to the WHO questionnaire, 14 stated that 
such a rescheduling would result in impeded access to treatment.
The documents presented to the meeting also discussed the legal 
considerations relating to the transfer of substances between conventions. 
Taking into account the text of the Single Convention on narcotic drugs 
and the United Nations Convention on psychotropic substances as well 
as offi cial commentaries to both Conventions and information included 
in WHO guidelines for the review of dependence-producing psycho-
active substances for international control, it is advisable that a substance 
should not be under more then one Convention. The WHO guidelines give 
guidance for the scheduling of new drugs, not yet scheduled, and on the 
choice between the Conventions for those drugs. They also give guidance 
for the scheduling of drugs already in the 1988 Convention. However, 
the guidelines do not give guidance on the transfer of a substance from 
the 1961 to the 1971 Convention or vice versa. A transfer of a substance 
from one Convention to the other would demand that the United Nations 
Commission on Narcotic Drugs take a simultaneous decision on deletion of
a substance from one Convention and adding it to the appropriate schedule 
of another Convention. A procedure for making a deletion from the 
schedules of the 1971 Convention is included in article 2 para. 6 of 
the Convention and requires a new assessment by WHO. A similar 
provision is included in the 1961 Convention article 3 para. 6(b). No 
provision is included, however, to indicate that these decisions are to be 
taken simultaneously.
Discussion
In the course of the meeting, members of the Committee expressed their 
views concerning various aspects of the current scheduling status of 
buprenorphine and the possible consequences, including legal aspects, of 
its rescheduling. It became evident that there were divergent views on the 
legal situation related to the transfer of substances between Conventions. 
The majority of the members considered however that the Expert Commit-
tee on Drug Dependence is not properly constituted to discuss legal issues 
related to international treaties.
Recommendation
Following review of the documents presented at the present meeting, which 
expanded the information made available at its thirty-third meeting, the 
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phine, and its expanded role in the treatment of opioid dependence. This 
pharmacological treatment of opioid dependence also contributes to the 
effi cient prevention and treatment of HIV/AIDS among opioid-dependent 
injecting drug users. Hence, the Committee did not recommend any change 
in the present scheduling of the substance in Schedule III of the 1971 
Convention.
2.2.2 Butorphanol (INN)
Substance identifi cation
Butorphanol (INN) is chemically (–)-17-(cyclobutylmethyl)morphinan-
3,14-diol.
Previous review
Butorphanol was pre-reviewed by the Committee at its thirty-third meet-
ing in September 2002 (3). The Committee recommended a critical review 
based on reports of abuse in some countries.
Similarity to known substances and effects on the central nervous system
Butorphanol is a synthetic opioid partial agonist analgesic with proper-
ties similar to other µ-opioid agonists such as scheduled substances 
buprenorphine and pentazocine. Although in radioligand-binding studies, 
butorphanol binds to both µ- and κ-opioid receptors, most of the observed 
behavioural, pharmacological and therapeutic effects appear to be due to its 
µ-opioid receptor agonist activity. Early studies suggested that butorphanol 
did not produce complete respiratory depressant effects and a “plateau” or 
“ceiling effect” was observed although more recent studies have challenged 
this notion. Moderate adverse effects on the central nervous system such as 
nausea/vomiting, headache, clamminess, sweatiness, asthenia, paraesthe-
sia, sedation, lethargy, anxiety, nervousness, euphoria, vertigo, dizziness, 
fl oating feeling, confusion and light-headedness are often reported follow-
ing both parenteral and intranasal administration.
Dependence potential
Early preclinical studies in laboratory animals suggested that butorphanol 
has lower abuse potential than full µ-agonists such as morphine. Human 
studies have indicated that although the incidence of butorphanol depen-
dence is infrequent, the withdrawal symptoms are very similar to those 
observed for morphine and buprenorphine. Information on the abuse potential 
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9of the different formulations of butorphanol shows that, from a pharmaco-
logical viewpoint, the trans-nasal preparation does not appear to differ in 
its abuse liability from the parenteral preparations. However, other non-
pharmacological factors such as availability and pattern of use can play 
critical roles in the likelihood of its abuse.
Actual abuse and/or evidence of likelihood of abuse
Abuse and diversion have been reported by very few countries — only two 
countries of the 74 that responded to the WHO questionnaire mentioned 
abuse of butorphanol.
Therapeutic usefulness
Butorphanol is used medically in humans as an analgesic for the relief of 
moderate-to-severe acute pain in certain specifi c conditions such as post-
surgical pain or migraine. Butorphanol was stated as being available for 
medical use in 21 of the 74 countries that responded to the WHO questionnaire. 
It is also used in veterinary medicine as an analgesic and antitussive agent. 
Recommendation
After reviewing the information available, the Committee considered that 
the level of abuse of butorphanol is low, limited to a few countries and does 
not pose a risk to public health. Therefore, the Committee did not recom-
mend scheduling of butorphanol.
2.2.3 Ketamine (INN)
Substance identifi cation
Ketamine (INN) is (±)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone. 
It contains a chiral centre, resulting in two enantiomers: S-(+)-ketamine and 
R-(–)-ketamine. Usually, the racemate is marketed but the more active S-(+)- 
enantiomer is increasingly present in commercially available preparations. 
Previous review
Ketamine was pre-reviewed by the Committee at its thirty-third meeting 
and critical review was recommended on the basis of reports of abuse in 
various countries (3).
Similarity to known substances and effects on the central nervous system
Ketamine is an arylcycloalkylamine structurally related to cyclidines such 
as phencyclidine. It is a non-competitive NMDA-receptor antagonist that 
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affects the central nervous system, resulting in hallucinations, disturbances 
in thinking, perception and motor function and may also produce mild re-
spiratory depression. It is used as an anaesthetic in both human and veteri-
nary medicine.
Dependence potential
Various animal models have shown that ketamine can produce a state of 
dependence, but reports of such dependence in humans are very limited. 
Tolerance may occur, but there is no evidence of a withdrawal syndrome.
Actual abuse and/or evidence of likelihood of abuse
Abuse has been reported in a number of countries in the Americas, Asia and 
Europe, sometimes in a mixture with other substances.
Therapeutic usefulness
Ketamine is widely used as an anaesthetic and analgesic in human and vet-
erinary medicine. Ketamine was stated as being available for medical use 
in 70 out of the 74 countries that answered the WHO questionnaire. It is 
included as a general anaesthetic in the 14th WHO Model List of Essential 
Medicines (10).
Recommendation
The Committee reviewed the information contained in the critical review 
document and concluded that this information was not suffi cient to war-
rant scheduling. However, in the course of the meeting, the Committee 
was informed that the United Nations Commission for Narcotic Drugs at 
its 49th session, held in March 2006, had adopted a draft resolution for 
transmission to ECOSOC, on the listing of ketamine as a controlled sub-
stance (11). The Committee requested the Secretariat to produce an updated 
version of the critical review and present it to the next meeting of the Expert 
Committee on Drug Dependence.
2.2.4 Khat (Catha edulis Forsk.)
Substance identifi cation
Khat refers to the leaves and the young shoots of the plant Catha edulis 
Forsk., a species belonging to the plant family Celastraceae. It is also writ-
ten and/or known as qat, q’at, kat, kath, gat, chat, tschat (Ethiopia), miraa 
(Kenya) and murungu. The dried leaves of khat are known as Abyssinian 
tea or Arabian tea.
10
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Previous review
Khat had been considered and reviewed by the Expert Committee many 
years previously, and at its thirty-third meeting the Committee pre-reviewed 
khat and concluded that there was suffi cient information on this substance 
to justify a critical review (3).
Similarity to known substances and effects on the central nervous system
The major psychoactive compounds found in khat are cathinone and cathine 
(norpseudoephedrine), which are scheduled under the 1971 Convention, 
and norephedrine, which is controlled under the 1988 Convention. The 
plant contains only the (–)-enantiomer of cathinone, which has the same 
absolute confi guration as S-(+)-amphetamine. Use of khat produces a state 
of euphoria and increased alertness. It can also produce insomnia and an 
increase in blood pressure, heart rate and body temperature. Psychotic 
reactions induced by khat use have also been reported.
Dependence potential
There is inconsistent data regarding the dependence potential of khat. With-
drawal symptoms after prolonged use may include loss of energy, lethargy, 
depressive feelings and slight trembling, but these symptoms are mild and 
resolve rapidly. Some tolerance may also develop.
Actual abuse and/or evidence of likelihood of abuse
Khat leaves are chewed habitually in the south-western part of the Arabian 
Peninsula and in East Africa. However, khat chewing has spread to other 
African countries and to Australia, Europe and the USA. Daily consump-
tion of khat may have negative effects on the social and economic life of the 
user. Khat is used in social gatherings.
Therapeutic usefulness
No confi rmed therapeutic usefulness has been identifi ed for khat. 
Recommendation
The Committee reviewed the data on khat and determined that the potential 
for abuse and dependence is low. The level of abuse and threat to public 
health is not signifi cant enough to warrant international control. Therefore, 
the Committee did not recommend the scheduling of khat. 
The Committee recognized that social and some health problems result 
from the excessive use of khat and suggested that national educational 
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campaigns should be adopted to discourage use that may lead to these 
adverse consequences.
2.2.5 Zopiclone (INN)
Substance identifi cation
Zopiclone (INN) is chemically 4-methyl-1-piperazinecarboxylic acid 
ester with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo-
[3,4-b]pyrazin-5-one.† Zopiclone has one chiral centre and therefore 
exists in two enantiomeric forms and a racemate. It is marketed under 
many trade names. Eszopiclone is the S-(+)-enantiomer and has also 
been marketed recently.
Previous review
Zopiclone was pre-reviewed by the Committee at its twenty-ninth meet-
ing, at which it recommended continued surveillance but not a critical 
review (12). Zopiclone underwent pre-review at its thirty-third meeting and 
the Committee recommended critical review based on its abuse liability and 
the signifi cant number of adverse drug reaction reports related to abuse, 
received by the international drug monitoring programme (3).
Similarity to known substances and effects on the central nervous system
The pharmacological properties of zopiclone are very similar to those of 
benzodiazepines and are believed to be related to the binding to the γ-amino-
butyric acid (GABA)/benzodiazepine receptor complex. Zopiclone has a 
sedative action on the central nervous system producing sedation, somno-
lence, fatigue and impairment of concentration. Other side-effects include 
nausea, dizziness, headache, sweating, hallucinations and agitation.
Dependence potential
Zopiclone use can lead in some instances to dependence with associated 
tolerance and withdrawal syndrome.
Actual abuse and/or evidence of likelihood of abuse
Some abuse of zopiclone has been reported by six of the countries that 
responded to the WHO questionnaire. In addition, abuse has been reported 
† This is synonymous with (5RS)-6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-
5-yl 4-methylpiperazine-1-carboxylate.
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as an adverse drug reaction to the WHO Programme for International Drug 
Monitoring. Zopiclone has also been implicated in some cases of sexual 
assault and robbery.
Therapeutic usefulness
Zopiclone is a widely prescribed hypnotic primarily used in the treatment 
of insomnia. Zopiclone was stated as being available for medical use in 34 
of the 59 countries that responded to the questions on this substance in the 
WHO questionnaire.
Recommendation
On the basis of available data concerning the pharmacological profi le 
and dependence potential of zopiclone, the Committee rated the abuse 
liability to be low, whereas the therapeutic usefulness is considerable. 
The Committee therefore came to the conclusion that zopiclone does 
not warrant international control and therefore did not recommend its 
scheduling.
3. Pre-review of psychoactive substances
The review of psychoactive substances by WHO is carried out in two steps. 
The fi rst step is referred to as pre-review; this is a preliminary review 
carried out by the Committee to determine whether or not a fully docu-
mented review (critical review) of the substance is required. The criterion 
for judgement as to whether critical review is necessary is whether or not 
WHO has information that might justify the scheduling of the substance. 
In the case of psychotropic substances, this requires information on actual 
abuse of the drug that causes signifi cant public health and social problems 
in more than one country.
In addition to the Secretariat, any member of the Expert Committee, 
or any representative of the other organizations invited to participate 
in the Expert Committee meeting, can submit a proposal to pre-review 
a substance together with supporting information. At the present meet-
ing, tramadol and gamma-hydroxybutyric acid were proposed by the 
Secretariat.
3.1 Gamma-hydroxybutyric acid
Gamma-hydroxybutyric acid (GHB) was pre-reviewed by the 
Committee at its thirty-fi rst meeting (13) and critically reviewed at its thirty-
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second meeting (7). It was recommended for inclusion in Schedule IV of 
the 1971 Convention and since 2001 has been placed in this Schedule by a 
decision of the United Nations Commission on Narcotic Drugs.
GHB is a naturally occurring compound found in very low concentrations 
in mammalian tissues. It is considered to act by binding to GHB-specifi c 
receptors and GABA
B 
receptors. At pharmacological doses it acts as a cen-
tral nervous system depressant. In some countries, GHB is used clinically 
as an anaesthetic agent and in the treatment of narcolepsy, narcolepsy with 
cataplexy, alcohol withdrawal and myoclonus-dystonia. GHB can produce 
physical dependence together with a withdrawal syndrome when the drug is 
abruptly discontinued following regular, chronic use. The withdrawal syn-
drome appears to be similar to that of other central nervous system depres-
sants. GHB and related products (gamma-butyrolactone and 1,4-butane-
diol) have been abused for their purported sexual performance-enhancing 
and growth-promoting effects as well as their euphoric effects. There have 
been reports of GHB being used to facilitate sexual assault. The toxicity 
of GHB is dose-dependent and there have been numerous instances of 
fatal and non-fatal GHB intoxication in many countries. The mode of abuse 
frequently involves other substances such as methylenedioxy-N-methylam-
phetamine (MDMA) and alcohol. Use and abuse of GHB appears to occur 
mainly in Australia, Europe and the USA.
Recommendation
The Committee considered additional data regarding its abuse liability and 
toxicity and recommended that a new critical review of GHB would be 
appropriate to consider its possible rescheduling. 
3.2 Tramadol (INN)
Tramadol (INN) is (±)-trans-2-[(dimethylamino)methyl]-1-(3-methoxy-
phenyl)cyclohexanol. It was critically reviewed at the thirty-third meet-
ing of the Committee in 2002, but the Committee decided that the 
information available at that time was not suffi cient to recommend 
international control of tramadol, although it was adequate to recom-
mend that WHO keep the drug under surveillance (3). Subsequently, the 
substance was presented by the WHO Secretariat for pre-review at the 
present meeting.
Tramadol is a centrally acting synthetic opioid analogue of codeine with 
a weak affi nity for the opioid receptors. It has additional monoaminergic 
activity (serotonin and noradrenaline re-uptake inhibition and α
2
-adrener-
14
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gic stimulation) producing a combined analgesic effect. The O-desmethyl 
metabolite is also pharmacologically active owing to signifi cant µ-opioid 
receptor affi nity. Tramadol induces analgesia, but is associated with less 
respiratory depression than other opioids and has no signifi cant cardiac 
effects. It has been found to reduce the seizure and sweating thresholds, 
and to reduce postoperative shivering. Subjective effects include euphoria. 
Reported adverse effects have included: dizziness, headache, agitation, 
nausea, vomiting and seizures. Overdose has been reported to result in 
tachycardia, convulsions, respiratory depression and coma. Other central-
nervous-system depressant or monoamine antidepressant compounds may 
exacerbate any toxic effects. There have been some reported instances of 
non-fatal and fatal tramadol intoxication worldwide, but these are few in 
comparison to total patient exposure.
Preclinical studies in animals indicated that tramadol may have a low 
abuse potential. Clinical studies and postmarketing surveillance pro-
grammes have found a possibility of dependence and abuse, particularly 
in patients with a previous history of opioid dependence or abuse. Post-
marketing surveillance programmes have shown a rate of abuse of 
0.5–1 per 100 000 patients (1997–2003). This fi gure included generic 
products since 2002 and tramadol with paracetamol combinations during 
1997–2003.
Data from various monitoring organizations reported some instances of 
smuggling and diversion but did not show any increasing trend in tramadol 
abuse and there was no evidence of illicit manufacture.
Recommendation
Following review of the documents presented at the present meeting, which 
expanded the information made available at the thirty-third meeting, the 
Committee considered that, even after a recent major increase in the extent 
of its use because of its therapeutic usefulness, tramadol continues to show 
a low level of abuse. Hence, the Committee concluded that there was not 
suffi cient evidence to justify a critical review.
4. Substances identifi ed for future pre-review
4.1 Gamma-butyrolactone (GBL)
During the pre-review of GHB, the Committee noted information relating 
to the abuse of GBL itself (convertible to GHB in the body) and suggested 
this substance for pre-review.
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4.2 1,4-Butanediol
During the pre-review of GHB, the Committee noted information relating 
to the abuse of 1,4-butanediol itself (convertible to GHB in the body) and 
suggested this substance for pre-review.
5. Guidelines for the WHO review of dependence-
producing psychoactive substances for 
international control
5.1 Amending the current version of the guidelines
International control of narcotic drugs and psychotropic substances is 
based on two treaties: the 1961 United Nations Single Convention on 
Narcotic Drugs and the 1971 United Nations Convention on Psycho-
tropic Substances. Both Conventions include schedules listing substances 
that are subject to appropriate control measures. The Conventions also 
established mechanisms for expanding and modifying the schedules and 
designated the United Nations Commission on Narcotic Drugs as the 
body authorized to adopt pertinent decisions concerning the scheduling 
of substances.
The Conventions specify the role of WHO as the institution designated 
to provide the United Nations Commission for Narcotic Drugs with 
appropriate information and evaluations related to medical, scientifi c and 
public health aspects of scheduling individual substances. Such assessment 
may pertain to substances that are not yet under international control, but 
also, to amendment of existing schedules or to deletion of substances from 
a schedule.
The responsibility for the assessment of substances for international control
has been entrusted within WHO to the Expert Committee on Drug 
Dependence, which reviews relevant information and gives its advice to the 
Director-General of WHO. The review is carried out with the considerable 
assistance of the WHO Secretariat according to a procedure approved by 
the WHO Executive Board. The current version of the procedure is included 
in the WHO document WHO/EDM/QSM/2000.5 entitled Guidelines for 
the WHO review of dependence-producing psychoactive substances for 
international control which was approved by the WHO Executive Board in 
decision EB105 in 2000 (14).
During its thirty-third meeting, the Expert Committee noted certain issues 
related to the scheduling of some substances for which no specifi c advice 
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exists in the current guidelines. The Committee therefore requested that the 
WHO Secretariat develop additional guidelines that would be suitable for 
amending their present text. A draft of such supplementary guidelines was 
produced in 2003 and presented to the WHO Executive Board for review
and possible approval. The Executive Board discussed this proposal during
its 114th and 115th meetings and, at the 115th meeting, the Executive Board 
confi rmed the applicability of the current version of the guidelines and 
asked the Secretariat and the Expert Committee to continue their work on 
the issue (15, 16).
During its thirty-fourth meeting, the Committee took note of the decision 
of the Executive Board. The Committee asked the Secretariat to continue to 
provide proposals for the necessary amendments to the guidelines, taking 
into account new developments that relate to the needs of international 
control of dependence-producing psychoactive substances. The Committee 
also decided that to facilitate future opinions related to the scheduling of
psychoactive substances in situations that are not fully covered by the current 
version of the guidelines, it will proceed according to an interpretation of 
specifi c situations as described below in item 5.2. 
The Committee also considered that the impact of scheduling on the 
balance between medical availability and prevention of abuse of controlled 
substances should become a part of the critical review.
5.2 Interpretation of specifi c aspects of the guidelines
The Committee decided that the stage of “pre-review” described in the 
guidelines should pertain not only to the review of psychoactive substances 
that were not previously scheduled in international Conventions, but also to 
the initial step of the review of substances that have already been scheduled 
in either of the Conventions. If the situation arises in which such a substance 
has to be considered for rescheduling or for deletion from a schedule, as 
indicated in para. 13 of the Guidelines, such pre-review can be initiated by 
the WHO Secretariat, individual members of the Expert Committee, or by 
representatives of organizations invited to participate in the meetings of 
the Committee. A pre-review procedure can also be initiated in cases when
the Committee has recommended to the WHO Secretariat that a given 
substance should be subject to surveillance and its results indicate a need 
for such a review. 
With respect to the “critical review” stage of the procedure described 
in para. 15 of the guidelines, the Committee decided that this should 
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preferably be concluded during a single meeting. However, in cases where 
additional information concerning the substance under review is required, 
the Committee may decide that it will reach a fi nal opinion at a subsequent 
meeting.
5.3 Access to information necessary for the evaluation 
of substances
The Expert Committee decided to advise the Secretariat to draw the atten-
tion of countries to the fact that both the Conventions include procedures 
for informing the United Nations: where a party has information, which, in 
its opinion, might require an amendment to any of the Schedules, it should 
notify the Secretary-General and furnish him or her with the information in 
support of the notifi cation, after which the Secretary-General will transmit 
such notifi cation to WHO and others.
The countries committed themselves to follow these procedures when 
becoming party to the Conventions, but the Expert Committee found that
this procedure had not been followed by any country in recent years, 
although the Committee knows of cases in which this would have been 
appropriate. 
The Committee also advises the Secretariat to urge countries once more to 
respond to questionnaires sent out by WHO in the preparation process for 
the evaluation of substances.
6. Other matters
6.1 Activities of the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA)
Dr Roumen Sedefov, Project Manager for New Drugs and the Scientifi c
Committee at the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) based in Lisbon, Portugal, described the role of the 
European Union (EU) drugs agency. He also outlined the implementation 
process of the Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of new psychoactive 
substances. The Decision establishes a mechanism for the rapid exchange 
of information at EU level on new psychoactive substances that may pose a 
public health threat similar to that posed by those listed in the 1961 United 
Nations Single Convention on Narcotic Drugs and the 1971 United Nations 
Convention on Psychotropic Substances.
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6.2 Use of pharmacovigilance data for the assessment 
of dependence and abuse potential (procedures and 
methodology)
The Committee was informed by the Secretariat on the WHO Programme 
for International Drug Monitoring. The Programme dates back to 1968 and 
is run by the Secretariat, WHO Collaborating Centre (Uppsala Monitor-
ing Centre) and its National Centres (79 to date) and Associate Members 
(18 to date). The number of case-reports of adverse drug reactions in the 
WHO database exceeds 3.5 million — an annual increase of 160 000.
For the pre-reviews and critical reviews, data obtained from the WHO 
Collaborating Centre were incorporated into the review reports. However, 
the Committee made several suggestions that could improve the usefulness 
of the data. These included the use of comparison substances, selection of 
adverse reactions which are indicators of drug abuse, better specifi cation of 
the terms used and the use of denominator data, all of which could improve 
interpretation of the information.
It was agreed that the Secretariat would organize a discussion on how to 
make the best use of these data for the evaluation of dependence and abuse 
potential. Experts and others involved will be invited to participate. It was 
also agreed that the collaboration between the Expert Committee and the 
Programme would be intensifi ed.
6.3 Promotion of education and information on the appropriate 
use of psychoactive drugs
At its thirty-third meeting, the Expert Committee discussed the possible 
adverse consequences of the medical use of selective serotonin reuptake 
inhibitors (SSRIs) (3). The Committee recommended that SSRIs be placed 
on the agenda for consideration at the next meeting of the Committee, not 
in the context of control, but to promote education and information on the 
appropriate use of psychoactive drugs. For this reason the issue was on the 
agenda of the thirty-fourth meeting of the Committee, but was expanded 
to medicines that are currently under international control (controlled 
medicines).
In 2005, the World Health Assembly and ECOSOC requested the INCB 
and WHO to examine the feasibility of a possible assistance mechanism 
that would facilitate the adequate treatment of pain using opioid analgesics 
(resolutions ECOSOC 2005/25 and WHA58.22). During its thirty-
fourth meeting, the Committee noted — as it had already concluded on 
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other occasions — that access to controlled medicines is insuffi cient in 
many cases, and it was therefore regarded as appropriate to establish an 
assistance mechanism that addresses the access to and the rational use of 
such medicines. Therefore, the Committee agreed that it could play a role 
in the promotion of education and information on the appropriate use of 
controlled medicines. 
The Secretariat is working on a plan to improve access to and rational use 
of controlled medicines. The Committee recommended that a formal and 
regularly accessible forum would enhance the consultation of experts in this 
fi eld and the Expert Committee is willing to act as such.
6.4 Impact of international control on medical availability 
of substances
During the discussions, factors limiting the availability of drugs for 
medical use were identifi ed, including barriers inadvertently created by 
the application of laws and regulations. There are countries where stricter
measures are applied than are required by the Conventions. This is 
permissible, as the requirements of the Conventions are minimum require-
ments. However, the aims of the Conventions are to ensure availability 
for medical use as well as the prevention of abuse. It should be noted 
therefore that the Conventions do not require the parties to implement 
specifi c licensing for prescribing and dispensing controlled substances
for medical use, nor require permits for receiving these substances
therapeutically. Applying stricter measures than those required by the 
Conventions may hamper rational use of medicines. The appropriate 
national authorities should carefully consider whether any such measure 
currently in force could be modifi ed to permit access for patients in 
need. 
The scheduling of a substance may lead to signifi cant barriers to its 
availability as a medicine. In addition to measures of control stricter than 
those contemplated by the Conventions, as mentioned above, other reasons 
may include inadequate implementation of accompanying measures, such 
as failure to develop and submit accurate estimates and statistics to the 
INCB, inappropriate medical practices and insuffi cient recognition of the 
therapeutic usefulness of controlled medicines by medical professionals, 
legislators and law enforcement offi cers.
It was noted by the Committee that over 80% of the world’s population has 
no proper access to narcotic analgesics, if required. The Committee stressed 
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that the appropriate national authorities should be encouraged to cooperate 
with WHO in consultation with the INCB to assist in improving access to 
these medications.
The Committee requested the WHO Secretariat to suggest including on the 
proposed agenda of the next Committee meeting, a discussion of the impact 
of scheduling on the balance between medical availability of controlled 
substances and the prevention of their abuse.
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